

Appendix 5 (as supplied by the authors): Methodological quality of randomized controlled trials of rapid-acting insulin analogues in type 1 diabetes.

Study*	Jadad score for:			Total Jadad score	Allocation Concealment ?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Anderson <i>et al.</i> , 1997 ²⁴	1	0	0	1	Unclear	NR	Yes	1,008	48 (4.8%)
Anderson <i>et al.</i> , 1997 ³⁶	1	0	0	1	Unclear	NR	Yes	336 type 1	151(45%)
Annuzzi <i>et al.</i> , 2001 ²⁵	1	0	0	1	Unclear	NR	NR	85	5 (5.9%)
Bode and Strange, 2001 ²⁸	1	0	1	2	Unclear	NR	NR	29	1 (3.4%)
Bode <i>et al.</i> , 2002 ²⁷	1	0	1	2	Unclear	NR	NR	146	14 (9.6%)
Bott <i>et al.</i> , 2003 ²⁹	1	0	0	1	Unclear	NR	NR	424	NR
Caixàs <i>et al.</i> , 1998 ³⁰	1	0	0	1	Unclear	NR	NR	10	NR
Chan <i>et al.</i> , 2004 ³³	1	0	0	1	Unclear	NR	NR	12 type 1	NR
Ciofetta <i>et al.</i> , 1999 ³¹	1	0	0	1	Unclear	NR	NR	24	NR
Deeb <i>et al.</i> , 2001 ⁶³	1	0	1	2	Unclear	NR	NR	61	2 (3.3%)
Del Sindaco <i>et al.</i> , 1998 ⁶⁴	1	0	0	1	Unclear	NR	NR	69	NR
Fairchild <i>et al.</i> , 2000 ¹⁹	1	0	1	2	Unclear	NR	NR	70	0
Ferguson <i>et al.</i> , 2001 ⁶⁵	1	0	1	2	Unclear	NR	NR	39	5 (12.8%)
Ford-Adams <i>et al.</i> , 2003 ⁶⁶	1	0	1	2	Adequate	Partially	Yes	23	None
Gale, 2000 ⁶⁷	1	2	1	4	Unclear	Yes	Yes	93	6 (6.5%)
Garg <i>et al.</i> , 1996 ⁶⁸	1	0	1	2	Unclear	NR	No	39	2 (5.1%)

Study*	Jadad score for:			Total Jadad score	Allocation Concealment ?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Hedman <i>et al.</i> , 2001 ⁶⁹	1	0	1	2	Unclear	NR	Yes	12	None
Heller <i>et al.</i> , 1999 ⁷⁰	1	0	1	2	Unclear	NR	Yes	135	1 (0.7%)
Heller <i>et al.</i> , 2004 ⁷¹	2	1	1	4	Adequate	NR	NR	155	16 (10.3%)
Holcombe <i>et al.</i> , 2002 ⁷²	1	0	1	2	Unclear	NR	Yes	481	18 (3.7%)
Holleman <i>et al.</i> , 1997 ⁷³	1	0	1	2	Unclear	NR	Yes	199	10 (5.0%)
Home <i>et al.</i> , 1998 ⁷⁴	1	1	1	3	Unclear	NR	Yes	104	14 (13.5%)
Home <i>et al.</i> , 2000 ⁷⁵	1	0	1	2	Unclear	NR	Yes	1070	59 (5.5%)
Home <i>et al.</i> , 2006 ⁷⁶	1	0	1	2	Unclear	NR	Yes	753	155 (21%)
Iwamoto <i>et al.</i> , 2001 ⁷⁷	1	0	0	1	Unclear	NR	Yes	211	15 (7.1%)
Jacobs <i>et al.</i> , 1997 ⁷⁸	1	0	0	1	Unclear	NR	NR	12	NR
Jansson <i>et al.</i> , 1998 ⁸⁰	1	0	0	1	Unclear	NR	NR	84	NR
Johansson <i>et al.</i> , 2000 ⁸¹	1	0	1	2	Unclear	NR	Yes	41	0
Kotsanos <i>et al.</i> , 1997 ³⁹	1	0	1	2	Unclear	NR	NR	468 type 1	26 (2.8%)
Melki <i>et al.</i> , 1998 ⁸³	1	0	1	2	Unclear	NR	NR	39	1 (2.5%)
Provenzano <i>et al.</i> , 2001 ⁸⁵	2	0	0	2	Unclear	NR	NR	12	NR
Raskin <i>et al.</i> , 2001 ⁸⁷	1	0	1	2	Unclear	NR	Yes	58	4 (6.9%)

Study*	Jadad score for:			Total Jadad score	Allocation Concealment ?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Raskin <i>et al.</i> , 2000 ⁸⁶	1	0	1	2	Unclear	NR	Yes	882	67 (7.6%) after 6 months; additional 39 after subsequen t 6 months
Recasens <i>et al.</i> , 2003 ⁸⁸	1	0	0	1	Unclear	NR	NR	45	NR
Renner <i>et al.</i> , 1999 ⁸⁹	1	0	0	1	Unclear	NR	NR	113	NR
Roach <i>et al.</i> , 1999 ⁴⁸	1	0	1	2	Unclear	No	Yes	37 type 1	3 (3.0%)
Schmauss <i>et al.</i> , 1998 ⁴²	1	0	1	2	Unclear	NR	Yes	11	0
Tamás <i>et al.</i> , 2001 ⁵⁷	2	0	0	2	Unclear	NR	Yes	426	16 (3.5%)
Tubiana-Rufi <i>et al.</i> , 2004 ⁵⁸	1	0	1	2	Unclear	NR	No	29	2 (6.9%)
Tupola <i>et al.</i> , 2001 ⁴³	1	0	1	2	Unclear	NR	No	24	2 (8.3%)
Valle <i>et al.</i> , 2001 ⁵⁹	1	0	0	1	Unclear	NR	Yes	1,184	NR
Vignati <i>et al.</i> , 1997 ⁴⁴	2	0	1	3	Unclear	NR	NR	379 type 1	29 (4.1%)
Zinman <i>et al.</i> , 1997 ⁴⁵	1	1	1	3	Unclear	NR	Yes	30	0

NR=not reported.

*Citations of the studies are listed in the main article, available at www.cmaj.ca/cgi/content/full/180/4/385.